Short-duration Selective Brain Cooling for Patients Undergoing Mechanical Thrombectomy

Capital Medical University120 enrolled

Overview

To determine the efficacy and safety of short-duration intra-artery selective brain cooling in addition to mechanical thrombectomy in patients with acute ischemic stroke.

Acute ischemic stroke remains one of the leading causes of disability and death in both developed and developing countries. Using intravenous thrombolysis combined with intra-arterial therapy to recanalize occluded vessels in eligible patients is recommended by current guidelines. Five randomized clinical trials showed that modified thrombolysis in cerebral ischemia (mTICI) 2b/3 recanalization can be achieved in 59-88% of acute ischemic stroke patients with anterior circulation large artery occlusion，but only an average of 46% of patients have a favorable outcome (modified Rankin Scale score \[mRS\] 0-2). Therefore, new therapeutic strategies in addition to thrombectomy for acute ischemic stroke are urgently needed. As early as 1987, Busto et al. found that lowering of the brain temperature by only a few degrees during ischemia confers a marked neuroprotective effect. Therapeutic hypothermia has been suggested to be the most potent neuroprotective strategy in recent years5，and a number of clinical studies in patients with acute cerebral infarction also showed that mild hypothermia (33-35 ℃) can increase tolerance to ischemic insults and play a significant neuroprotective role after reperfusion. However, adverse events such as pneumonia, affecting up to 35% of treated patients occurs with hypothermia. Since selective brain cooling does not require a reduction in core body temperature, it is theoretically possible to avoid many serious adverse effects caused by whole body hypothermia. The investigators have previous shown that short-duration selective brain cooling by the intra-arterial infusion of cold saline combined with mechanical thrombectomy in acute ischemic stroke is feasible and safe. The efficacy of selective brain cooling in patients undergoing mechanical thrombectomy, however, is not established. The investigators therefore conducted this RCT study to explore the efficacy of short-duration selective brain cooling in patients with acute ischemic stroke who underwent mechanical thrombectomy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

120

Conditions

Hypothermia Stroke, Acute

Interventions

selective brain cooling by cold saline perfusionDRUG

During the procedure, a microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.

mechanical thrombectomyDEVICE

conventional mechanical thrombectomy using Solitaire

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Acute ischemic stroke within 6 hours from symptom onset/last seen well. * Occlusion (TIMI 0-1) of the basilar artery or distal intracranial carotid artery or middle (M1/M2) or anterior (A1/A2) cerebral artery as evidenced by CTA/MRA/DSA. * Age ≥18 and ≤80 * No significant pre-stroke functional disability (mRS ≤ 1) * The possibility to start treatment within 6 hours from onset. * Informed consent given Exclusion Criteria: * Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \> 3.0 * Baseline platelet count \< 50.000/µL * Baseline blood glucose of \< 50mg/dL or \>400mg/dl * Severe, sustained hypertension (SBP \> 220 mm Hg or DBP \> 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained below these levels using commonly used medications in China for these purposes (including iv antihypertensive drips), the patient can be enrolled. * Serious, advanced, or terminal illness with anticipated life expectancy of less than one year. * History of life threatening allergy (more than rash) to contrast medium * Subjects who has received iv t-PA treatment beyond 4.5 hours from the beginning of the symptoms. * Patients with acute stroke within the first 48 hours after percutaneous cardiac, cerebrovascular interventions and major surgery * Renal insufficiency with creatinine ≥ 3 mg/dl * Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission. * Subject participating in a study involving an investigational drug or device that would impact this study. * Cerebral vasculitis * Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, mRS score at baseline must be ≤ 1, which includes patients who are severely demented, require constant assistance in a nursing home type setting or who live at home but are not fully independent in activities of daily living (toileting, dressing, eating, cooking and preparing meals, etc.) * Unlikely to be available for 90 days follow-up (e.g. no fixed home address, visitor from overseas). * CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).

Locations (1)

Xuan Wu Hospital，Capital Medical University

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

Proportion of patients achieving favorable outcomes defined as mRS 0-2 at 90 days as evaluated by independent central assessors who are blinded to treatment

mRS 0-2

Time frame: 90 days

Secondary Outcomes

Dramatic early favorable response

an NIHSS of 0-2 or NIHSS improvement ≥ 8 points at 24 (-2/+12 hours) hours from randomization or before discharge if patient is discharged prior to the above time limit

Time frame: 24 hours

Final infarct volume evaluated on CT/MR at 24 hours (-2/+12 hours)

Time frame: 24 hours

The change of infarct volume compared with baseline.

Time frame: 24 hours

Vessel recanalization

Vessel recanalization evaluated by angiography (one of CT angiography , MR Angiography and conventional angiography) at 24 hours (-2/+12 hours) in both treatment groups

Time frame: 24 hours

Barthel Index at 90 days

Time frame: 90 days

NIHSS at 90 days

Time frame: 90 days

Proportion of patients achieving excellent favorable outcomes defined as mRS 0-1 at 90 days

mRS 0-1 at 90 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.